KR102086788B1 - 간암의 비-침습성 진단을 위한 특이적 바이오마커 세트 - Google Patents

간암의 비-침습성 진단을 위한 특이적 바이오마커 세트 Download PDF

Info

Publication number
KR102086788B1
KR102086788B1 KR1020167032783A KR20167032783A KR102086788B1 KR 102086788 B1 KR102086788 B1 KR 102086788B1 KR 1020167032783 A KR1020167032783 A KR 1020167032783A KR 20167032783 A KR20167032783 A KR 20167032783A KR 102086788 B1 KR102086788 B1 KR 102086788B1
Authority
KR
South Korea
Prior art keywords
lys
leu
ser
gly
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167032783A
Other languages
English (en)
Korean (ko)
Other versions
KR20170021234A (ko
Inventor
코넬리아 윙 인 만
노만 펑 맨 와이
벤자민 치 인 와이
빙 로우 웡
Original Assignee
드래곤 빅토리 디벨롭먼트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/321,867 external-priority patent/US9506925B2/en
Priority claimed from US14/321,870 external-priority patent/US9885718B2/en
Application filed by 드래곤 빅토리 디벨롭먼트 리미티드 filed Critical 드래곤 빅토리 디벨롭먼트 리미티드
Publication of KR20170021234A publication Critical patent/KR20170021234A/ko
Application granted granted Critical
Publication of KR102086788B1 publication Critical patent/KR102086788B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
KR1020167032783A 2014-07-02 2014-07-31 간암의 비-침습성 진단을 위한 특이적 바이오마커 세트 Expired - Fee Related KR102086788B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/321,867 US9506925B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
US14/321,870 US9885718B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
US14/321,867 2014-07-02
US14/321,870 2014-07-02
PCT/US2014/049038 WO2016003479A1 (en) 2014-07-02 2014-07-31 Specific biomarker set for non-invasive diagnosis of liver cancer

Publications (2)

Publication Number Publication Date
KR20170021234A KR20170021234A (ko) 2017-02-27
KR102086788B1 true KR102086788B1 (ko) 2020-03-09

Family

ID=55019816

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167032783A Expired - Fee Related KR102086788B1 (ko) 2014-07-02 2014-07-31 간암의 비-침습성 진단을 위한 특이적 바이오마커 세트

Country Status (12)

Country Link
EP (1) EP3164711A4 (enExample)
JP (2) JP2017520763A (enExample)
KR (1) KR102086788B1 (enExample)
CN (2) CN105319362B (enExample)
AU (2) AU2014399919B2 (enExample)
CA (1) CA2939912C (enExample)
MY (2) MY179845A (enExample)
NZ (1) NZ722492A (enExample)
SG (1) SG11201606106SA (enExample)
TW (1) TWI700493B (enExample)
UY (1) UY36200A (enExample)
WO (1) WO2016003479A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106383231B (zh) * 2016-09-02 2020-03-17 四川大学 一种诊断肝癌的标记物组合及其应用
GB201619954D0 (en) * 2016-11-25 2017-01-11 Oncimmune Ltd Antibody assay
KR102175265B1 (ko) 2019-03-13 2020-11-06 충남대학교산학협력단 Txndc7을 포함하는 간세포암종 진단 또는 예후 예측용 바이오마커 조성물
CN110646615B (zh) * 2019-08-27 2021-07-13 南方医科大学 肝纤维化的生物学标志物、治疗靶点及其用途
WO2023282916A1 (en) 2021-07-09 2023-01-12 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
ES2987661T3 (es) 2020-07-10 2024-11-15 Guardant Health Inc Métodos de detección de reordenamientos genómicos utilizando ácidos nucleicos libres de células
CN113502328A (zh) * 2021-05-27 2021-10-15 深圳市人民医院 检测样本中标志物表达水平的试剂在制备用于检测或诊断乳腺癌的试剂盒中的应用
CN113777295B (zh) * 2021-09-15 2024-03-19 江南大学 用于检测肿瘤标志物pd-l1的高灵敏度量子点探针、制备方法及应用
CN113956344A (zh) * 2021-10-14 2022-01-21 江南大学 一种新型治疗肝癌的fgf类似物及其应用
CN114113611B (zh) * 2021-12-13 2023-07-14 郑州大学 一种用于肝癌诊断的生物标志物及检测试剂盒

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040059519A1 (en) 1998-08-18 2004-03-25 Chandler Van S. Multiplexed analysis of clinical specimens apparatus and methods
WO2004052392A2 (en) 2002-12-11 2004-06-24 The University Of Birmingham Cancer immunotherapy using polycomb proteins
JP2005099001A (ja) * 2003-08-31 2005-04-14 Kyogo Ito 抗ペプチド抗体測定法とペプチドワクチンのワクチン候補選択方法
JP2008026290A (ja) 2006-07-25 2008-02-07 Ehime Univ 腫瘍マーカ、腫瘍診断キットおよび腫瘍マーカの測定方法
JP2012047543A (ja) 2010-08-25 2012-03-08 Yamaguchi Univ 自己抗体の検出方法
WO2013049704A3 (en) 2011-09-28 2013-05-23 Armune Biosciences, Inc. Method and system of particle-phage epitope complex

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893844B1 (en) * 1998-09-22 2005-05-17 Long Yu DNA encoding a new human hepatoma derived growth factor and producing method thereof
US7387881B2 (en) * 2001-09-19 2008-06-17 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
US20040241653A1 (en) * 2001-12-31 2004-12-02 Elena Feinstein Methods for identifying marker genes for cancer
GB0406215D0 (en) * 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
WO2005123944A1 (en) * 2004-06-18 2005-12-29 Roche Diagnostics Gmbh Use of protein pdx1 as a marker for breast cancer
US20110281284A1 (en) * 2007-08-10 2011-11-17 Otsuka Pharmaceutical Co., Ltd Novel liver cancer marker
US8512963B2 (en) * 2009-11-25 2013-08-20 The Johns Hopkins University Detection and quantitation of full-length thioredoxin (TRX) and truncated thioredoxin (TRX 80) in complex samples
US9523680B2 (en) * 2010-06-30 2016-12-20 Ambergen, Inc. Global Proteomic screening of random bead arrays using mass spectrometry imaging
EP2678448A4 (en) * 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040059519A1 (en) 1998-08-18 2004-03-25 Chandler Van S. Multiplexed analysis of clinical specimens apparatus and methods
WO2004052392A2 (en) 2002-12-11 2004-06-24 The University Of Birmingham Cancer immunotherapy using polycomb proteins
JP2005099001A (ja) * 2003-08-31 2005-04-14 Kyogo Ito 抗ペプチド抗体測定法とペプチドワクチンのワクチン候補選択方法
JP2008026290A (ja) 2006-07-25 2008-02-07 Ehime Univ 腫瘍マーカ、腫瘍診断キットおよび腫瘍マーカの測定方法
JP2012047543A (ja) 2010-08-25 2012-03-08 Yamaguchi Univ 自己抗体の検出方法
WO2013049704A3 (en) 2011-09-28 2013-05-23 Armune Biosciences, Inc. Method and system of particle-phage epitope complex

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Chang Kyu Heo et al, BMB Reports (2012), vol 45, no 12 pp 677-685.
Dai Liping et al, Clinical Immunology (2014.03.22.), vol 152, no 1, pp 127-139.
Junko Akada et al, Proteome Science (2013), 11:33, pp 1-10.
Kalpa Patel et al, International Journal of Cancer (2010), vol 129, no 1, pp 133-142.
Salama O et al, Biosensors and Bioelectronice (2006), vol 22, pp 1508-1516.

Also Published As

Publication number Publication date
AU2014399919B2 (en) 2019-10-24
JP2020160082A (ja) 2020-10-01
SG11201606106SA (en) 2016-08-30
CA2939912A1 (en) 2016-01-07
CN107478842B (zh) 2020-10-16
AU2014399919A1 (en) 2016-08-11
JP2017520763A (ja) 2017-07-27
WO2016003479A1 (en) 2016-01-07
HK1224370A1 (zh) 2017-08-18
CN105319362B (zh) 2018-07-13
EP3164711A1 (en) 2017-05-10
NZ722492A (en) 2019-09-27
UY36200A (es) 2016-01-29
MY195045A (en) 2023-01-04
TWI700493B (zh) 2020-08-01
CN107478842A (zh) 2017-12-15
AU2017232129A1 (en) 2017-10-12
CN105319362A (zh) 2016-02-10
TW201602579A (zh) 2016-01-16
MY179845A (en) 2020-11-18
CA2939912C (en) 2019-04-16
HK1248803A1 (zh) 2018-10-19
KR20170021234A (ko) 2017-02-27
AU2017232129B2 (en) 2018-10-25
EP3164711A4 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
KR102086788B1 (ko) 간암의 비-침습성 진단을 위한 특이적 바이오마커 세트
Robinson et al. Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma
JP6075881B2 (ja) 乳癌のバイオマーカー
RU2016109642A (ru) Антитела и методы анализа для обнаружения рецептора фолиевой кислоты 1
CN109975549B (zh) 肿瘤来源IgG在胰腺癌诊断或预后中的用途
Hu et al. High RSF-1 expression correlates with poor prognosis in patients with gastric adenocarcinoma
US20200386761A1 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
JP6639408B2 (ja) デオキシハイプシン・シンターゼ遺伝子を指標として用いる動脈硬化及びがんの検出方法
JP6361943B2 (ja) 補体因子ｂタンパク質に特異的に結合する抗体及び糖鎖抗原１９−９タンパク質に特異的に結合する抗体を含む膵臓癌診断用キット
US10620209B2 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
KR101649591B1 (ko) 신규 급성백혈병의 진단용 마커
US9885718B2 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
JP5574522B2 (ja) 癌マーカー及び癌細胞の検査方法
KR101324773B1 (ko) 단백질의 위치 변화 확인을 통한 신경교종의 진단 및 치료 방법
HK1248803B (zh) 用於肝癌的无创诊断的特异性生物标志物组
HK1224370B (zh) 用於肝癌的无创诊断的特异性生物标志物组
Sun et al. Functional screen for secreted proteins by monoclonal antibody library and
CN120441694A (zh) 膜联蛋白a1特异性抗体、使用方法及其诊断试剂盒
Wang et al. Expression of B7-H4 in ovarian cancer and its clinical significance
JP2012225822A (ja) ＡＰＣ−ｂｉｎｄｉｎｇｐｒｏｔｅｉｎＥＢ１を用いた大腸癌の診断、治療法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240304

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240304